Tuberculosis and Respiratory Diseases

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma

Taehee Kim, Yoon Jin Cha, Yoon Soo Chang

Tuberc Respir Dis. 2020;83(1):51-60. Published online August 31, 2019
DOI: https://doi.org/10.4046/trd.2019.0026

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect onEGFRMutation–Positive Lung Adenocarcinoma

Taehee Kim, Yoon Jin Cha, Yoon Soo Chang

Tuberculosis and Respiratory Diseases. 2020;83(1):51

Link1 Link2 Link3

P37.26 Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression using Routine Clinical and Conditioned Archives of Non-Small-Cell Lung Cancer

T.J. Kim

Journal of Thoracic Oncology. 2021;16(3):S453

Link1 Link2

Evaluation of the prognostic impact of SP263-evaluated PD-L1 expression in patients with non-small cell lung cancer (NSCLC) stage III treated with radio-chemotherapy

Jan Wagner, Julia Roeper, Lukas Heukamp, Markus Falk, Kay Willborn, Frank Griesinger

. 2022;

Link1 Link2

P2.09-14 Evaluation on Inter-Assay Consistency and Inter-Reader Precision for PD-L1 Assays: Ventana SP263 and Dako 22C3 in Non-Small Cell Lung Cancer

D. Lin, X. Yang

Journal of Thoracic Oncology. 2019;14(10):S774

Link1 Link2

Correlation between 22C3–PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma

Eriko Miyawaki, Haruyasu Murakami, Toshiaki Takahashi

Journal of Thoracic Oncology. 2018;13(5):e79-e81

Link1 Link2

Re: The correlation between PD-L1 expression and metabolic parameters of 18FDG PET/CT and the prognostic value of PD-L1 in non-small cell lung cancer

Mouqing Huang, Jia Guo

Clinical Imaging. 2023;93:115-116

Link1 Link2

PD-L1 expression in uncommon EGFR-mutant non-small cell lung cancer and its response to immunotherapy

Y. Fan, K. Chen

Annals of Oncology. 2019;30:v510

Link1 Link2 Link3

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion

Hitomi Sakai, Masayuki Takeda, Kazuko Sakai, Yasushi Nakamura, Akihiko Ito, Hidetoshi Hayashi, Kaoru Tanaka, Kazuto Nishio, Kazuhiko Nakagawa

Lung Cancer. 2019;127:59-65

Link1 Link2

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives

Sue Youn Kim, Tae-Eun Kim, Chan Kwon Park, Hyoung-Kyu Yoon, Young Jo Sa, Hyo Rim Kim, In Sook Woo, Tae-Jung Kim

Cancers. 2022;14(13):3138

Link1

60 Afatinib in EGFR mutation positive advanced non-small cell lung cancer

R.S. Davies, A.E. Brewster, M.R. Button, J.F. Lester

Lung Cancer. 2016;91:S22

Link1 Link2